Results 261 to 270 of about 174,020 (338)

Simultaneous Intracranial and Spinal Hemorrhage Following Tenecteplase Thrombolysis for ST‐Elevation Myocardial Infarction: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Central nervous system (CNS) hemorrhage is a serious complication of intravenous thrombolysis. Tenecteplase, a fibrin‐specific thrombolytic agent, has a lower risk of hemorrhage than other agents. We report the first documented case of simultaneous intracranial and spinal hemorrhage following intravenous administration of tenecteplase.
Thamalee Palliyaguru   +4 more
wiley   +1 more source

Disseminated Invasive Aspergillosis in a Young Patient With Chronic Alcohol Use and Seemingly Preserved Immunocompetence: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Invasive aspergillosis, though typically seen in immunocompromised patients, can also affect immunocompetent individuals and mimic pulmonary malignancy. This case highlights the importance of considering fungal infections in the differential diagnosis of chronic respiratory symptoms, particularly in patients with risk factors such as heavy ...
Kumail Khandwala   +4 more
wiley   +1 more source

Genetic variants underlying precancerous conditions of hepatocellular carcinoma

open access: yesInternational Journal of Cancer, Volume 158, Issue 3, Page 488-502, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 80% of cases worldwide. While chronic hepatitis B and C infections remain primary risk factors, emerging evidence highlights the increasing contributions of metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease
Jonathan Jaime G. Guerrero   +7 more
wiley   +1 more source

Effects of immune checkpoint inhibitors on the pulmonary circulation in lung cancer patients

open access: yesInternational Journal of Cancer, Volume 158, Issue 3, Page 682-696, 1 February 2026.
What's new? Immune checkpoint inhibitors (ICIs) are effective against various cancers, but as more patients receive these therapies, more immune‐related adverse events (irAEs) emerge. Recent studies have suggested that ICIs are associated with an increase in pulmonary artery diameter and the ratio between pulmonary artery diameter and aortic diameter ...
Yao Xu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy